NITROGEN MUSTARD AS A THERAPEUTIC AGENT FOR HODGKIN'S DISEASE, LYMPHOSARCOMA AND LEUKEMIA

Abstract

The effects of di([beta]-chloroethyl) methyl amine HC1 in 77 patients; 28 with Hodgkin''s disease, 11 with lymphosarcoma, 26 with leukemia, and 12 with miscellaneous diseases are described. The dose, 0.1 mg./kg., was given intraven. daily for 4-6 days. In general, the effects were similar to those produced by radiation. Therapeutic results were particularly good in Hodgkin''s disease and remissions were induced in several, even, who were considered to be roentgen-ray resistant. Chronic myelocytic leukemia was usually well controlled. The results were less gratifying in the other diseases although a striking response was occasionally seen in lymphosarcoma. Nausea and vomiting occurred in most recipients and leukopenia and thrombocytopenia in many. No serious complication resulted.